You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 9, 2024

~ Buy the BRAFTOVI (encorafenib) Drug Profile, 2024 PDF Report in the Report Store ~

BRAFTOVI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Braftovi, and what generic alternatives are available?

Braftovi is a drug marketed by Array Biopharma Inc and is included in one NDA. There are thirteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and ninety-six patent family members in fifty-three countries.

The generic ingredient in BRAFTOVI is encorafenib. One supplier is listed for this compound. Additional details are available on the encorafenib profile page.

DrugPatentWatch® Generic Entry Outlook for Braftovi

Braftovi was eligible for patent challenges on June 27, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 5, 2033. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for BRAFTOVI?
  • What are the global sales for BRAFTOVI?
  • What is Average Wholesale Price for BRAFTOVI?
Drug patent expirations by year for BRAFTOVI
Drug Prices for BRAFTOVI

See drug prices for BRAFTOVI

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BRAFTOVI
Generic Entry Date for BRAFTOVI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for BRAFTOVI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute (NCI)Phase 1
Deciphera Pharmaceuticals LLCPhase 1/Phase 2
PfizerPhase 2

See all BRAFTOVI clinical trials

Paragraph IV (Patent) Challenges for BRAFTOVI
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
BRAFTOVI Capsules encorafenib 75 mg 210496 3 2022-06-27

US Patents and Regulatory Information for BRAFTOVI

BRAFTOVI is protected by twenty-five US patents and three FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of BRAFTOVI is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting BRAFTOVI

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF MELANOMA

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST

Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-- pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY

3,4-diarylpyrazoles as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF MELANOMA

3,4-diarylpyrazoles as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST

3,4-diarylpyrazoles as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY

3,4-diarylpyrazoles as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST

3,4-diarylpyrazoles as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF MELANOMA MEDIATED BY A B-RAF PROTEIN KINASE

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST

Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-- pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-.alpha. inhibitor
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-- pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF MELANOMA

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: INDICATED IN COMBINATION WITH BINIMETINIB FOR THE TREATMENT OF MELANOMA WITH A BRAF MUTATION

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF MELANOMA WITH A BRAF MUTATION

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH CETUXIMAB, FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC COLORECTAL CANCER (CRC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, AFTER PRIOR THERAPY

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA- APPROVED TEST

Compounds and compositions as protein kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: BRAFTOVI IS A KINASE INHIBITOR INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting BRAFTOVI

ENCORAFENIB IS INDICATED IN COMBINATION WITH BINIMETINIB, FOR THE TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC MELANOMA WITH A BRAF V600E OR V600K MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
Exclusivity Expiration: ⤷  Sign Up

ENCORAFENIB IN COMBINATION WITH BINIMETINIB, IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF ADULT PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A BRAF V600E MUTATION, AS DETECTED BY AN FDA-APPROVED TEST
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-002 Jun 27, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Array Biopharma Inc BRAFTOVI encorafenib CAPSULE;ORAL 210496-001 Jun 27, 2018 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for BRAFTOVI

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Pierre Fabre Medicament Braftovi encorafenib EMEA/H/C/004580
Encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy
Authorised no no no 2018-09-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for BRAFTOVI

When does loss-of-exclusivity occur for BRAFTOVI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 2045
Patent: COMBINACIONES FARMACEUTICAS
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 13299841
Patent: Pharmaceutical combinations comprising a B-Raf inhibitor, an EGFR inhibitor and optionally a P13K-alpha inhibitor
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2015002384
Patent: combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 79548
Patent: COMBINAISONS PHARMACEUTIQUES COMPRENANT UN INHIBITEUR DE B-RAF, UN INHIBITEUR D'EGFR ET FACULTATIVEMENT UN INHIBITEUR DE PI3K ALPHA (PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 15000294
Patent: Combinaciones farmaceuticas que comprenden un inhibidor de b-raf, un inhibidor del receptor del factor de crecimiento epidermico y opcionalmente un inhibidor pi3halpha y uso en el tratamiento de una enfermedad proliferativa.
Estimated Expiration: ⤷  Sign Up

China

Patent: 4519887
Patent: Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 00273
Patent: Combinaciones farmaceúticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0190537
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 82440
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 15008695
Patent: COMBINACIONES FARMACÉUTICAS QUE COMPRENDEN UN INHIBIDOR DE B-RAF, UN INHIBIDOR DE EGFR Y OPCIONALMENTE UN INHIBIDOR DE PI3K-ALFA
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 8420
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ИНГИБИТОР B-RAF, ИНГИБИТОР EGFR И, НЕОБЯЗАТЕЛЬНО, ИНГИБИТОР PI3K-АЛЬФА (PHARMACEUTICAL COMBINATIONS COMPRISING A B-Raf INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Patent: 1590332
Patent: ФАРМАЦЕВТИЧЕСКИЕ КОМБИНАЦИИ, СОДЕРЖАЩИЕ ИНГИБИТОР B-RAF, ИНГИБИТОР EGFR И, НЕОБЯЗАТЕЛЬНО, ИНГИБИТОР PI3K-АЛЬФА
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 82440
Patent: COMBINAISONS DE MEDICAMENTS CONTENANT UN INHIBITEUR DE B-RAF, UN INHIBITEUR DE L'EGFR, ET OPTIONELLEMENT UN INHIBITEUR PI3K-ALPHA (PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Patent: 74904
Patent: COMBINAISONS PHARMACEUTIQUES COMPRENANT UN INHIBITEUR B-RAF, UN INHIBITEUR D'EGFR ET ÉVENTUELLEMENT UN INHIBITEUR PI3K-ALPHA (PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Guatemala

Patent: 1500025
Patent: COMBINACIONES FARMACÉUTICAS QUE COMPRENDEN UN INHIBIDOR DE B-RAF, UN INHIBIDOR DE EGFR Y OPCIONALMENTE UN INHIBIDOR DE PI3K-ALFA
Estimated Expiration: ⤷  Sign Up

Hong Kong

Patent: 04976
Patent: 種包含 抑制劑, 抑制劑,及視需要 抑制劑的醫藥組合 (PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR B-RAF EGFR PI3K-ALPHA)
Estimated Expiration: ⤷  Sign Up

Patent: 11831
Patent: 包含 抑制劑、 抑制劑和任選 α抑制劑的藥物組合 (PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR B-RAF EGFR PI3K)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 42877
Estimated Expiration: ⤷  Sign Up

India

Patent: 0DEN2015
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 6934
Patent: תכשיר רוקחי המכיל מעכב b-raf, מעכב egfr ומעכב pi3k-alpha אופציונאלי (Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 42396
Estimated Expiration: ⤷  Sign Up

Patent: 95024
Estimated Expiration: ⤷  Sign Up

Patent: 74669
Estimated Expiration: ⤷  Sign Up

Patent: 15524472
Patent: B−Raf阻害薬、EGFR阻害薬及び場合によってはPI3K−α阻害薬を含む組合せ医薬
Estimated Expiration: ⤷  Sign Up

Patent: 18109022
Patent: B−Raf阻害薬、EGFR阻害薬及び場合によってはPI3K−α阻害薬を含む組合せ医薬 (PHARMACEUTICAL COMBINATIONS COMPRISING B-Raf INHIBITOR, AND EGFR INHIBITOR AND OPTIONALLY PI3K-α INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Patent: 20019780
Patent: B−Raf阻害薬、EGFR阻害薬及び場合によってはPI3K−α阻害薬を含む組合せ医薬 (PHARMACEUTICAL COMBINATIONS COMPRISING B-RAF INHIBITOR, AND EGFR INHIBITOR AND OPTIONALLY PI3K-α INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Jordan

Patent: 0130236
Patent: تركيبات صيدلانية تشتمل على مثبط B-RAF ومثبط EGFR ومثبط اختياري لــPI3K ALPHA (PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 82440
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 6031
Patent: PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 9403
Patent: COMBINACIONES FARMACÉUTICAS QUE COMPRENDEN UN INHIBIDOR DE B-RAF, UN INHIBIDOR DE EGFR, Y OPCIONALMENTE UN INHIBIDOR DE PI3K-ALFA. (PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR.)
Estimated Expiration: ⤷  Sign Up

Patent: 15001732
Patent: COMBINACIONES FARMACEUTICAS QUE COMPRENDEN UN INHIBIDOR DE B-RAF, UN INHIBIDOR DE EGFR, Y OPCIONALMENTE UN INHIBIDOR DE P13K-ALFA. (PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR.)
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 829
Patent: Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 3940
Patent: Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 150673
Patent: COMBINACIONES FARMACEUTICAS
Estimated Expiration: ⤷  Sign Up

Patent: 191655
Patent: COMBINACIONES FARMACEUTICAS
Estimated Expiration: ⤷  Sign Up

Philippines

Patent: 015500246
Patent: PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 82440
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 82440
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 734
Patent: FARMACEUTSKE KOMBINACIJE KOJE OBUHVATAJU B-RAF INHIBITOR, EGFR INHIBITOR I OPCIONO PI3K-ALFA INHIBITOR (PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201500321Y
Patent: PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 82440
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2112885
Estimated Expiration: ⤷  Sign Up

Patent: 150040905
Patent: B-RAF 억제제, EGFR 억제제 및 임의로 PI3K-알파 억제제를 포함하는 제약 조합물 (PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 17911
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 07754
Estimated Expiration: ⤷  Sign Up

Patent: 1410247
Patent: Pharmaceutical combinations
Estimated Expiration: ⤷  Sign Up

Tunisia

Patent: 15000027
Patent: PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR
Estimated Expiration: ⤷  Sign Up

Turkey

Patent: 1904980
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 5786
Patent: ФАРМАЦЕВТИЧНА КОМБІНАЦІЯ, ЩО МІСТИТЬ ІНГІБІТОР B-Raf, ІНГІБІТОР EGFR ТА, НЕОБОВ'ЯЗКОВО, ІНГІБІТОР РІ3K-? (PHARMACEUTICAL COMBINATIONS COMPRISING A B-RAF INHIBITOR, AN EGFR INHIBITOR AND OPTIONALLY A PI3K-ALPHA INHIBITOR)
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BRAFTOVI around the world.

Country Patent Number Title Estimated Expiration
Colombia 6612222 Compuestos y composiciones como inhibidores de cinasa de proteina ⤷  Sign Up
Eurasian Patent Organization 201170249 3,4-ДИАРИЛПИРАЗОЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ ⤷  Sign Up
China 104519887 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor ⤷  Sign Up
Ecuador SP23034537 FORMULACIONES FARMACEUTICAS ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for BRAFTOVI

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2470526 19C1013 France ⤷  Sign Up PRODUCT NAME: ENCORAFENIB SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/18/1314 20180924
2470526 C02470526/01 Switzerland ⤷  Sign Up PRODUCT NAME: ENCORAFENIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66795 01.11.2019
2470526 CA 2019 00012 Denmark ⤷  Sign Up PRODUCT NAME: ENCORAFENIB I ALLE FORMER BESKYTTET AF GRUNDPATENTET; REG. NO/DATE: EU/1/18/1314 20180924
2470526 2019C/508 Belgium ⤷  Sign Up DETAILS ASSIGNMENT: CHANGE OF OWNER(S), MERGE
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.